Edition:
United Kingdom

Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

96.81USD
19 Jun 2018
Change (% chg)

$1.56 (+1.64%)
Prev Close
$95.25
Open
$94.23
Day's High
$98.50
Day's Low
$94.23
Volume
133,853
Avg. Vol
155,979
52-wk High
$98.50
52-wk Low
$50.91

Latest Key Developments (Source: Significant Developments)

Agios Announces Proposed Offering Of Common Stock
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.SAYS IT IS OFFERING TO SELL UP TO $400 MILLION OF ITS COMMON STOCK IN A PUBLIC OFFERING.SAYS ALL OF SHARES IN OFFERING ARE TO BE SOLD BY AGIOS.  Full Article

Agios Outlines Key 2018 Priorities Expanding Clinical And Research Programs To Drive Long Term Value
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS OUTLINES KEY 2018 PRIORITIES EXPANDING CLINICAL AND RESEARCH PROGRAMS TO DRIVE LONG TERM VALUE.AGIOS PHARMACEUTICALS INC - SEVENTH IND SUBMISSION FOR A DHODH INHIBITOR FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES EXPECTED IN 4Q 2018.AGIOS - 2017 YEAR END CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES OF $568M FUNDS EXPANDED CLINICAL & RESEARCH PROGRAMS THROUGH END OF 3Q 2019.AGIOS PHARMACEUTICALS INC - TWO PIVOTAL TRIALS IN PYRUVATE KINASE DEFICIENCY WITH AG-348, ACTIVATE-T TO INITIATE IN 1Q 2018 AND ACTIVATE IN 2Q 2018.AGIOS PHARMACEUTICALS INC - PHASE 2 PROOF OF CONCEPT TRIAL OF AG-348 IN THALASSEMIA PLANNED FOR 4Q 2018.AGIOS PHARMACEUTICALS INC - MAT2A INHIBITOR AG-270 EXPECTED TO ENTER PHASE 1 DOSE-ESCALATION TRIAL IN MTAP-DELETED TUMORS IN 1Q 2018.  Full Article

Agios Submits New Drug Application To The FDA For Ivosidenib
Tuesday, 26 Dec 2017 

Dec 26 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS SUBMITS NEW DRUG APPLICATION TO THE FDA FOR IVOSIDENIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY AML AND AN IDH1 MUTATION.AGIOS PHARMACEUTICALS INC - EXPECTS TO INITIATE PHASE 1 TRIAL FOR AG-270 IN Q1 OF 2018.AGIOS PHARMACEUTICALS INC - ‍ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR AG-270 TARGETING MTAP-DELETED TUMORS​.  Full Article

Agios Pharmaceuticals Files For Potential Mixed Shelf Offering
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS PHARMACEUTICALS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Agios presents updated phase 1 data from dose expansion cohort of ivosidenib
Friday, 17 Nov 2017 

Nov 17 (Reuters) - Agios Pharmaceuticals Inc :Agios presents updated phase 1 data from dose expansion cohort of ivosidenib (AG-120) in patients with IDH1 mutant positive glioma.Agios Pharmaceuticals Inc - ‍ivosidenib well-tolerated in patients with low grade glioma​.Agios Pharmaceuticals Inc - ‍additional preclinical data demonstrate that ivosidenib and AG-881 suppress 2-HG levels in brain tumor mouse models​.Agios Pharmaceuticals Inc - ‍there were 5 patients with serious adverse events (SAE) and all were deemed unrelated to study treatment​.Agios Pharmaceuticals - ‍preliminary data suggest that both molecules suppress oncometabolite D-2-hydroxyglutarate in an orthotopic brain tumor model​.Agios Pharmaceuticals - study ‍to refine imaging methodology, assess biological effects of IDH inhibitors in perioperative study planned for H1 of 2018​.  Full Article

Agios reports Q3 revenue $11.4 million
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Agios Pharmaceuticals Inc :Agios reports third quarter 2017 financial results.Q3 revenue $11.4 million versus I/B/E/S view $9.8 million.Agios Pharmaceuticals Inc - Qtrly ‍net loss per share $1.59.  Full Article

Agios Pharmaceuticals Inc Q1 net loss was $66.2 million
Thursday, 4 May 2017 

May 4 (Reuters) - Agios Pharmaceuticals Inc :Agios reports first quarter 2017 financial results.Agios Pharmaceuticals Inc - net loss for quarter ended March 31, 2017 was $66.2 million, compared to a net loss of $23.2 million for quarter ended March 31, 2016.Agios Pharmaceuticals Inc - collaboration revenue was $10.5 million for quarter ended March 31, 2017, compared to $31.3 million.  Full Article

Agios Pharmaceuticals appoints Andrew Hirsch as chief financial officer
Tuesday, 16 Aug 2016 

Agios Pharmaceuticals Inc : Appoints Andrew Hirsch as chief financial officer . Glenn Goddard, senior vice president of finance, will be leaving company at end of September to pursue other opportunities .Andrew Hirsch most recently served as president and chief executive officer of Bind Therapeutics.  Full Article

Agios Pharmaceuticals reports qtrly loss per share $1.47
Thursday, 4 Aug 2016 

Agios Pharmaceuticals Inc : Agios reports second quarter 2016 financial results . Collaboration revenue was $7.0 million for quarter ended June 30, 2016, compared to $13.2 million for comparable period in 2015 .Qtrly loss per share $1.47.  Full Article

BRIEF-Agios Qtrly Loss Per Share $1.63

* AGIOS PROVIDES BUSINESS UPDATE ON DISCOVERY RESEARCH STRATEGY AND PIPELINE, PROGRESS ON CLINICAL PROGRAMS, COMMERCIAL LAUNCH PREPARATIONS AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AT INVESTOR DAY